Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is evaluated for the treatment of diffuse large B-cell lymphoma. It is designed to direct cytotoxic T cells selectively.
Lead Product(s): Epcoritamab,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2024
Lead Product(s) : Epcoritamab,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Two Data Analyses Show Epcoritamab Induces Durable Complete Responses
Details : Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is evaluated for the treatment of diffuse large B-cell lymphoma. It is designed to direct cytotoxic T cells selectively.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
December 09, 2024
Details:
Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.
Lead Product(s): Ibrutinib,Rituximab
Therapeutic Area: Oncology Brand Name: Imbruvica
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldens...
Details : Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.
Product Name : Imbruvica
Product Type : Small molecule
Upfront Cash : Not Applicable
December 23, 2020
Details:
Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or more off treatment.
Lead Product(s): Venetoclax,Rituximab
Therapeutic Area: Oncology Brand Name: Venclexta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Lead Product(s) : Venetoclax,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® in Ch...
Details : Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or mor...
Product Name : Venclexta
Product Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2020
Details:
Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in WM.
Lead Product(s): Ibrutinib,Rituximab
Therapeutic Area: Oncology Brand Name: Imbruvica
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
AbbVie Reports IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenstr...
Details : Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in...
Product Name : Imbruvica
Product Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2020
Details:
Ituxredi (rituximab) is an anti-CD20 monoclonal antibody, which is indicated for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia & rheumatoid arthritis.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Brand Name: Ituxredi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2024
Dr. Reddy’s Receives Positive CHMP Opinion from EMA for its Proposed Rituximab Biosimilar
Details : Ituxredi (rituximab) is an anti-CD20 monoclonal antibody, which is indicated for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia & rheumatoid arthritis.
Product Name : Ituxredi
Product Type : Large molecule
Upfront Cash : Not Applicable
July 29, 2024
Details:
DRL_RI is being developed as a biosimilar of Rituxan/MabThera (rituximab), a CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and pemphigus vulgaris.
Lead Product(s): Rituximab
Therapeutic Area: Immunology Brand Name: DRL_RI
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Details : DRL_RI is being developed as a biosimilar of Rituxan/MabThera (rituximab), a CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, ...
Product Name : DRL_RI
Product Type : Large molecule
Upfront Cash : Not Applicable
July 12, 2023
Details:
DRL_RI is being developed as a biosimilar of rituximab, CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris etc.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Dr. Reddy’s Successfully Completes Full Set Of Clinical Studies Of Its Rituximab Biosimilar For ...
Details : DRL_RI is being developed as a biosimilar of rituximab, CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris et...
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
January 19, 2023
Details:
Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Pfizer’s ADCETRIS Combo for Relapsed/Refractory DLBCL
Details : Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 12, 2025
Details:
MK-2140 (zilovertamab vedotin) is an investigational ADC that targets ROR1 receptor. It is being evaluated for the treatment of previously untreated patients with diffuse large b-cell lymphoma.
Lead Product(s): Zilovertamab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Brand Name: MK-2140
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2025
Lead Product(s) : Zilovertamab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Starts Phase 3 waveLINE-010 Study of Zilovertamab Vedotin in DLBCL
Details : MK-2140 (zilovertamab vedotin) is an investigational ADC that targets ROR1 receptor. It is being evaluated for the treatment of previously untreated patients with diffuse large b-cell lymphoma.
Product Name : MK-2140
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 06, 2025
Details:
ALE.F02 (lixudebart) is a claudin 1 inhibitor antibody, which is currently being evaluated for antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Lead Product(s): Lixudebart,Rituximab,GlucoCorticoid
Therapeutic Area: Immunology Brand Name: ALE.F02
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Lixudebart,Rituximab,GlucoCorticoid
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alentis Announces Positive Results for Lixudebart in ANCA-RPGN Liver Fibrosis
Details : ALE.F02 (lixudebart) is a claudin 1 inhibitor antibody, which is currently being evaluated for antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Product Name : ALE.F02
Product Type : Antibody
Upfront Cash : Inapplicable
January 09, 2025
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE